Stable pharmaceutical choline succinate substance

By adding 0.01-2.00 wt.% of O-(2-hydroxyethoxyethyl)trimethylammonium to choline succinate, the stability of the pharmaceutical substance is enhanced, maintaining the active substance's content and properties during storage, addressing the stability issues of choline succinate.

WO2026142461A1PCT designated stage Publication Date: 2026-07-02OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU ELLARA

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU ELLARA
Filing Date
2025-10-14
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Existing pharmaceutical substances of choline succinate lack stability during long-term storage, leading to significant changes in chemical, physical, and pharmacological properties, which compromises the efficacy of medicinal products based on them.

Method used

Incorporating 0.01-2.00 wt.% of the compound O-(2-hydroxyethoxyethyl)trimethylammonium into choline succinate enhances its stability by using nuclear magnetic resonance spectroscopy for quantitative detection.

Benefits of technology

The incorporation of the compound (I) maintains the stability of choline succinate within the specified range, ensuring minimal changes in active substance content during storage, thereby preserving the pharmaceutical product's integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure RU2025050353_02072026_PF_FP_ABST
    Figure RU2025050353_02072026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to the field of pharmaceutics, and more particularly to a pharmaceutical choline succinate substance for use in the preparation of medicaments. Proposed is a pharmaceutical choline succinate substance containing 0.01-2.00 wt.% of a compound of formula (I). The obtained substance has elevated stability.
Need to check novelty before this filing date? Find Prior Art